NanoViricides, Inc. (NNVC)
USD 0.99
(-4.81%)
USD 0.99
(-4.81%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 1.35 Million USD | -33.21% |
| 2023 | 2.03 Million USD | 392.75% |
| 2022 | 412.83 Thousand USD | 17.57% |
| 2021 | 351.14 Thousand USD | -83.72% |
| 2020 | 2.15 Million USD | -24.29% |
| 2019 | 2.84 Million USD | 222.94% |
| 2018 | 881.94 Thousand USD | -86.8% |
| 2017 | 6.68 Million USD | -50.82% |
| 2016 | 13.58 Million USD | 9.55% |
| 2015 | 12.4 Million USD | -22.32% |
| 2014 | 15.96 Million USD | 90.1% |
| 2013 | 8.39 Million USD | 371.89% |
| 2012 | 1.77 Million USD | 203.08% |
| 2011 | 587.17 Thousand USD | -76.26% |
| 2010 | 2.47 Million USD | 379.65% |
| 2009 | 515.71 Thousand USD | -49.66% |
| 2008 | 1.02 Million USD | 20.55% |
| 2007 | 849.88 Thousand USD | -43.0% |
| 2006 | 1.49 Million USD | 2159.13% |
| 2005 | 66 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 2.44 Million USD | 20.35% |
| 2024 Q4 | 1.35 Million USD | 67.06% |
| 2024 Q3 | 813.33 Thousand USD | -14.48% |
| 2024 Q2 | 951.07 Thousand USD | -61.15% |
| 2023 FY | 2.03 Million USD | 392.75% |
| 2023 Q3 | 348.74 Thousand USD | -24.94% |
| 2023 Q2 | 464.59 Thousand USD | -10.37% |
| 2023 Q1 | 518.35 Thousand USD | 25.56% |
| 2023 Q4 | 2.03 Million USD | 483.31% |
| 2022 FY | 412.83 Thousand USD | 17.57% |
| 2022 Q2 | 344.28 Thousand USD | -60.4% |
| 2022 Q4 | 412.83 Thousand USD | 6.75% |
| 2022 Q3 | 386.73 Thousand USD | 12.33% |
| 2022 Q1 | 869.46 Thousand USD | 147.61% |
| 2021 FY | 351.14 Thousand USD | -83.72% |
| 2021 Q2 | 339.3 Thousand USD | -81.82% |
| 2021 Q1 | 1.86 Million USD | -13.47% |
| 2021 Q3 | 871.34 Thousand USD | 156.8% |
| 2021 Q4 | 351.14 Thousand USD | -59.7% |
| 2020 Q3 | 2.21 Million USD | -43.19% |
| 2020 Q2 | 3.89 Million USD | 46.65% |
| 2020 FY | 2.15 Million USD | -24.29% |
| 2020 Q1 | 2.65 Million USD | -6.73% |
| 2020 Q4 | 2.15 Million USD | -2.57% |
| 2019 Q2 | 1.16 Million USD | -16.42% |
| 2019 FY | 2.84 Million USD | 222.94% |
| 2019 Q1 | 1.39 Million USD | 57.86% |
| 2019 Q3 | 2.67 Million USD | 130.08% |
| 2019 Q4 | 2.84 Million USD | 6.38% |
| 2018 Q4 | 881.94 Thousand USD | -72.38% |
| 2018 Q2 | 7.8 Million USD | 15.73% |
| 2018 Q3 | 3.19 Million USD | -59.1% |
| 2018 Q1 | 6.74 Million USD | 0.98% |
| 2018 FY | 881.94 Thousand USD | -86.8% |
| 2017 FY | 6.68 Million USD | -50.82% |
| 2017 Q4 | 6.68 Million USD | 8.21% |
| 2017 Q3 | 6.17 Million USD | -49.47% |
| 2017 Q2 | 12.21 Million USD | -12.71% |
| 2017 Q1 | 13.99 Million USD | 3.04% |
| 2016 Q1 | 11.58 Million USD | -6.56% |
| 2016 Q2 | 12.46 Million USD | 7.57% |
| 2016 Q3 | 14.33 Million USD | 15.01% |
| 2016 Q4 | 13.58 Million USD | -5.24% |
| 2016 FY | 13.58 Million USD | 9.55% |
| 2015 Q3 | 13.74 Million USD | -19.63% |
| 2015 Q1 | 12.19 Million USD | -23.64% |
| 2015 FY | 12.4 Million USD | -22.32% |
| 2015 Q4 | 12.4 Million USD | -9.75% |
| 2015 Q2 | 17.09 Million USD | 40.24% |
| 2014 Q3 | 8.92 Million USD | -29.64% |
| 2014 FY | 15.96 Million USD | 90.1% |
| 2014 Q4 | 15.96 Million USD | 78.96% |
| 2014 Q1 | 13.35 Million USD | 59.08% |
| 2014 Q2 | 12.67 Million USD | -5.1% |
| 2013 Q3 | 7.75 Million USD | 454.81% |
| 2013 Q1 | 1.55 Million USD | -12.5% |
| 2013 FY | 8.39 Million USD | 371.89% |
| 2013 Q4 | 8.39 Million USD | 8.32% |
| 2013 Q2 | 1.39 Million USD | -10.26% |
| 2012 Q2 | 1.17 Million USD | 18.35% |
| 2012 Q1 | 991.15 Thousand USD | 68.8% |
| 2012 Q4 | 1.77 Million USD | 121.33% |
| 2012 FY | 1.77 Million USD | 203.08% |
| 2012 Q3 | 804.07 Thousand USD | -31.45% |
| 2011 FY | 587.17 Thousand USD | -76.26% |
| 2011 Q4 | 587.17 Thousand USD | -27.48% |
| 2011 Q3 | 809.7 Thousand USD | -54.73% |
| 2011 Q2 | 1.78 Million USD | 2.47% |
| 2011 Q1 | 1.74 Million USD | -29.44% |
| 2010 Q3 | 958.72 Thousand USD | -23.97% |
| 2010 FY | 2.47 Million USD | 379.65% |
| 2010 Q2 | 1.26 Million USD | 126.34% |
| 2010 Q4 | 2.47 Million USD | 158.02% |
| 2010 Q1 | 557.11 Thousand USD | 8.03% |
| 2009 Q2 | 558.63 Thousand USD | -44.23% |
| 2009 Q4 | 515.71 Thousand USD | -23.67% |
| 2009 FY | 515.71 Thousand USD | -49.66% |
| 2009 Q1 | 1 Million USD | -2.23% |
| 2009 Q3 | 675.65 Thousand USD | 20.95% |
| 2008 Q1 | 760.88 Thousand USD | -10.47% |
| 2008 Q2 | 385.59 Thousand USD | -49.32% |
| 2008 Q3 | 513.21 Thousand USD | 33.1% |
| 2008 Q4 | 1.02 Million USD | 99.63% |
| 2008 FY | 1.02 Million USD | 20.55% |
| 2007 Q3 | 773.36 Thousand USD | 11.56% |
| 2007 Q2 | 693.24 Thousand USD | 45.88% |
| 2007 FY | 849.88 Thousand USD | -43.0% |
| 2007 Q1 | 475.22 Thousand USD | -68.13% |
| 2007 Q4 | 849.88 Thousand USD | 9.89% |
| 2006 Q4 | 1.49 Million USD | 0.0% |
| 2006 FY | 1.49 Million USD | 2159.13% |
| 2005 FY | 66 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 9.14 Million USD | 85.145% |
| Ampio Pharmaceuticals, Inc. | 2.37 Million USD | 42.812% |
| Armata Pharmaceuticals, Inc. | 142.02 Million USD | 99.043% |
| Actinium Pharmaceuticals, Inc. | 45.06 Million USD | 96.985% |
| Azitra, Inc. | 2.2 Million USD | 38.303% |
| Can-Fite BioPharma Ltd. | 3.74 Million USD | 63.727% |
| Chromocell Therapeutics Corporation | 6.54 Million USD | 79.227% |
| Calidi Biotherapeutics, Inc. | 18.25 Million USD | 92.556% |
| CEL-SCI Corporation | 17.31 Million USD | 92.152% |
| iBio, Inc. | 7.41 Million USD | 81.663% |
| Lineage Cell Therapeutics, Inc. | 38.99 Million USD | 96.516% |
| MAIA Biotechnology, Inc. | 7.08 Million USD | 80.834% |
| Matinas BioPharma Holdings, Inc. | 46.33 Million USD | 97.067% |
| Navidea Biopharmaceuticals, Inc. | 12.51 Million USD | 89.143% |
| NovaBay Pharmaceuticals, Inc. | 5.72 Million USD | 76.245% |
| Oragenics, Inc. | 1.79 Million USD | 24.436% |
| BiomX Inc. | 55.07 Million USD | 97.533% |
| BiomX Inc. | 55.07 Million USD | 97.533% |
| Protalix BioTherapeutics, Inc. | 50.86 Million USD | 97.329% |
| Palatin Technologies, Inc. | 10.85 Million USD | 87.481% |
| Scorpius Holdings, Inc. | 22.74 Million USD | 94.026% |
| Theriva Biologics, Inc. | 20.51 Million USD | 93.376% |